Summary Using RNA extracted from human tumour samples removed during surgery, we have analysed expression of mRNA for parathyroid hormone-related protein (PTHrP) and for the PTH/PTHrP receptor by RT-PCR in a panel of human breast and colon tumours. All but 1 of 18 breast tumour samples expressed PTHrP, whereas receptor expression was detected in 11 of these. Expression of the PTH/PTHrP receptor was found in three out of four metastatic lesions, including one sample in which no receptor was detected in the primary tumour. PTHrP expression was also detected in five colon tumours, and receptor expression detected in two of these. These results demonstrate that PTHrP and the PTHrP receptor are also co-expressed in breast tumours in vivo and provide further evidence that PTHrP may be an important autocrine/paracrine growth factor in breast cancer.
Humoral hypercalcaemia of malignancy (HCM) is mediated by tumour cell secretion of parathyroid hormone-related protein (PTHrP) , a polypeptide that shares some N-terminal homology with the systemic calcium-regulating hormone parathyroid hormone (PTH) (Goltzman et al, 1989 ; Martin and Suva, 1989) . PTH and PTHrP bind to the same cell-surface receptor (the type 1 PTH/PTHrP receptor) (Abou-Samra et al, 1992) , and PTHrP exerts many effects on target cells in common with PTH, including elevation of intracellular cAMP (Birch et al, 1995) and [Ca2+] , (Donahue et al, 1988; Schofl et al, 1991) . PTHrP has been localized to a range of normal and fetal tissues (Moniz et al, 1990 ), but its physiological role is not yet clear. It is believed, however, to be a paracrine or autocrine regulator of cell function.
PTHrP production has been identified in normal (Thiede and Rodan, 1988) and malignant mammary tissue by immunocytochemistry (Bundred et al, 1991; Powell et al, 1991; Bundred et al, 1992; Edwards et al, 1995 and in situ hybridization (Vargas et al, 1992) , and PTHrP has been detected in the supernatants of cultured mammary epithelial cells (Ferrari et al, 1992) . In transgenic mice that overexpress PTHrP, there is profound breast hyperplasia (Wysolmerski et al, 1993) . These findings suggest a role for PTHrP in the regulation of mammogenesis. Furthermore, a range of findings indicate that PTHrP may have a role to play in the growth or development of growth of breast cancer. Cultured breast cancer cells and cell lines have been shown to produce PTHrP (Walsh et al, 1992; Francini et al, 1993) , and 60% of human breast carcinomas were found to express PTHrP immunocytochemically (Southby et al, 1990) .
In a previous study, we demonstrated expression of the PTH/PTHrP receptor by a range of human breast cancer cell lines, and showed that a breast cancer cell line that expressed the (Birch et al, 1995 Co-expression of PTHrP and its receptor in tumours 1097
shown to express mRNA for PTHrP by RT-PCR (Figure 1) . mRNA for the PTH/PTHrP receptor was detected in five of ten infiltrating ductal breast cancers, one of four invasive lobular breast cancers, three of four metastatic breast cancers and two of five colon cancers (Figure 2 ). Of the metastatic tumours that expressed mRNA for the receptor, one of these was a metastasis from a primary tumour (group 1) which did not express the receptor. Southern hybridization confirmed the identity of the PCR products and detected low-level receptor mRNA in one further infiltrating ductal carcinoma.
DISCUSSION
We have demonstrated the expression of mRNA for PTHrP in 18 surgically excised breast tumour samples, and mRNA for the PTH/PTHrP receptor in 11 of these. The expression and/or production of PTHrP by a variety of tumour cells has been widely reported, with breast tumours particularly common producers of the protein. Although one clearly shown consequence of PTHrP production by tumours is the well-described hypercalcaemia associated with malignancy, the widespread detection of PTHrP in cancers has led investigators to consider the possibility that PTHrP might be involved in the growth or progression of the tumour. If PTHrP does regulate tumour growth, then the susceptible tumour cells must possess a surface receptor for the molecule. We have recently demonstrated the expression of PTH/PTHrP receptors by human breast cancer cell lines, and have shown that one cell line that expresses the receptor (MCF-7) also proliferates in response to PTHrP in vitro. Similarly, Bowcott et al (1994) and Iwamura et al (1994) have shown mitogenic responses to PTHrP in PTHrPexpressing prostate cancer cell lines. Tumour cell lines can therefore express both PTHrP and its receptor and thereby respond to the PTHrP in an autocrine fashion.
In the current study, we have demonstrated expression of both PTHrP and its receptor in samples of surgically removed primary breast tumour tissue. PTHrP mRNA was detected in all breast cancer samples studied, but receptor expression was detected in only 11 of these tumours. In a previous study, receptor expression was detected in three of six breast cancer cell lines; thus, only a proportion of breast cancers possess the capacity to respond to PTHrP. Immunohistochemisty studies have detected PTHrP in 88% of breast tumours from patients with bone metastases compared with 52% of tumours without metastases (Bundred et al, 1991) . This may indicate that PTHrP production by cancer cells could predispose to the development of bone metastases. However, in the current study, PTHrP mRNA was also detected in all five colon tumours, although with a lower signal strength, and to date the vast majority of tumours we have tested have been positive for PTHrP mRNA. Although there was also a signal for the PTH/PTHrP receptor in a minority of the colon tumours, this signal was considerably weaker than in the breast cancer samples. The growth of breast cancer cells and their aggressiveness may be related both to PTHrP expression and to their ability to respond (via the PTH/PTHrP receptor) to the autocrine or paracrine effects of local PTHrP production, and co-expression of PTHrP and its receptor may be an important factor in promoting metastatic spread.
We have detected, in one instance, changes in PTHrP receptor expression between a primary tumour and a metastasis which could represent the selection of a metastatic cell type which was more aggressive and responsive to the growth-promoting effects of PTHrP. In animal models, inhibition of PTHrP production by 1, 25-dihydroxy-vitamin D3 and its analogues has prevented the development of hypercalcaemia and inhibited growth of tumours (Haq et al, 1993) . Taken in conjunction with our data, this would support the contention that PTHrP can act in an autocrine or paracrine fashion to promote the growth of tumours. The data also suggest that there could be therapeutic benefits in switching off PTHrP production and/or antagonizing the effects of PTHrP at the receptor level.
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